Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prognostic and predictive markers in cancer.

Barbara A Conley¹, Sheila E Taube

¹Medical Oncology Clinical Research Unit, Center for Cancer Research, NCI, NIH, DHHS, Bethesda, MD 20892, USA. conleyb@mail.nih.gov

Disease Markers

|August 24, 2004

Summary

Developing effective cancer treatments requires rigorous evaluation of new prognostic and predictive markers. This review outlines a methodology to assess the clinical utility of these cancer markers, ensuring their reliable integration into patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026

Same author

Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

JCO precision oncology·2026

Same author

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

JCO precision oncology·2026

Same author

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

JCO precision oncology·2025

Same author

PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

JCO precision oncology·2025

Area of Science:

Oncology
Genomics
Molecular Biology

Background:

Advances in genomics and molecular biology offer potential for personalized cancer treatment.
Despite numerous identified markers, few are integrated into clinical practice due to evaluation challenges.

Purpose of the Study:

To present a methodology for the clinical evaluation of prognostic and predictive cancer markers.
To address pitfalls in early marker evaluation and optimize assay development.
To provide examples of clinical trials for assessing marker utility.

Main Methods:

Review of existing literature on marker evaluation.
Proposal of criteria for identifying clinically useful markers.
Discussion of assay methodology optimization.

Related Experiment Videos

Outline of clinical trial designs for validation.

Main Results:

Identified critical criteria for evaluating potential cancer markers.
Highlighted common pitfalls in early-stage marker assessment.
Emphasized the need for robust assay validation.
Proposed a framework for clinical trials to confirm marker utility.

Conclusions:

A standardized methodology is crucial for validating prognostic and predictive cancer markers.
Rigorous evaluation ensures that new markers provide clinically relevant information beyond standard factors.
Successful implementation of this methodology can accelerate the integration of novel diagnostics into cancer care.